According to the latest financial report of Immuno-Biological Laboratories, the latest earnings per share (TTM) for the company is 17.84. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about Immuno-Biological Laboratories's free cash flow? The latest report shows it as 76.07M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Immuno-Biological Laboratories shows that the company's current ratio is 4.75, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Immuno-Biological Laboratories, the quick ratio is 3.47, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of Immuno-Biological Laboratories? The latest ROE figure is 14.05%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Immuno-Biological Laboratories, the total asset return on investment (ROA) is 10.88%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Immuno-Biological Laboratories's latest financial report to see how their gross margin is doing - currently at 71.10%.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Immuno-Biological Laboratories, the net profit margin is 61.91%, which is a good sign for its profitability.